29 results
424B7
RLAY
Relay Therapeutics Inc
16 Nov 23
Prospectus with selling stockholder info
4:16pm
, we announced additional interim clinical data for RLY-4008 with a data cut-off date of August 1, 2022 that was presented at the European Society … . In June 2023, we presented complete first-in-human dose escalation data for RLY-4008 at the 2023 American Society of Clinical Oncology Annual Meeting
8-K
RLAY
Relay Therapeutics Inc
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
consistent with the analysis reported by the Company at the European Society for Medical Oncology Congress 2022.
Most treatment-related adverse
8-K
EX-99.1
wi6r8go1
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
ox1ggq1a6qbrrxg
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm
8-K
EX-99.1
6rftmu8jc60x0cb 74
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm
8-K
EX-99.1
axu7uo mah
4 May 23
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.1
52s55cd46zt 7tq
3 Nov 22
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:11pm
424B5
ucnnqm i04vh
13 Sep 22
Prospectus supplement for primary offering
5:19pm
424B5
96ni8d
12 Sep 22
Prospectus supplement for primary offering
7:35am
8-K
0ywg4huk
12 Sep 22
Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023
6:05am
8-K
EX-99.1
l5naw6vaa5vz c3b3sfy
12 Sep 22
Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023
6:05am
8-K
ytt79
8 Sep 22
Regulation FD Disclosure
6:31am
8-K
EX-99.1
g68 3cgmhp37rzx70
4 Aug 22
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:32pm